Healthy Business Matters

How Employers Can Get Better Healthcare for Less: Breaking the Status Quo with Dan Cosgrove

Healthcare costs are rising fast yet employees are getting less care. So where is the money going? In this episode, Dr. Andrew White sits down with Dan Cosgrove of Better Benefits USA to break down what’s really driving employer healthcare costs—and what you can do about it. They share practical strategies to help companies reduce spend while improving benefits. From tax strategies to plan design to preventative care, this conversation shows how employers can stop playing defense at renewal—and start taking control. If you’re tired of double-digit increases and want a smarter path forward, this episode is for you. In this Episode: * Why healthcare costs keep rising * Self-funded vs. fully insured strategies * How preventative care reduces claims * The “Netflix model” of healthcare * Ways to lower premiums without cutting benefits * Tax strategies most employers miss * How broker incentives impact decisions * Why value-based care is growing * Real examples of cost savings Key Insights * Better benefits and lower costs can go together * Many employers are overpaying without realizing it * Small changes can create major savings * Preventative care is a major opportunity * Incentives drive the system—understand them to win Who This Episode Is For: Employers looking to cut costs without cutting benefits CFOs and HR leaders tired of tough renewals Brokers who want to bring smarter solutions Business owners ready for a better approach Healthy Business Matters helps CFOs, HR leaders, brokers, and operators make smarter healthcare decisions. Each episode focuses on real strategies to reduce risk, control costs, and improve outcomes—so you can walk into your next renewal with a plan. About Dan Cosgrove: Dan Cosgrove is the CEO of Better Benefits USA, a certified 501(c)(3) nonprofit on a mission to close the healthcare gap on care, cost, and coverage for hardworking Americans. Before this, he worked at Procter & Gamble, Nike, and Berkshire Hathaway, and later as a financial strategist and consultant helping organizations improve performance, benefits strategy, and employee wellbeing. Dan is passionate about the structural incentives behind U.S. healthcare, including how brokers, insurers, and employers interact, and why many cost-saving efforts fail due to misaligned incentives. This is why his non profit created the “sustainable funding” model where they only earn revenue when measurable savings are delivered to clients. Dan also explores preventative care models, wellness programs, and tax-efficient benefit design to improve retention and employee health outcomes. Dan challenges the assumption that better healthcare must cost more, showing companies can often improve employee benefits without increasing spend. He urges leaders to question traditional healthcare incentives and whether they truly align with employers and employees. Resources & Links Better Benefits USA / Free Benefits Audit: https://betterbenefitsusa.org [https://findbetterbenefits.org/] LinkedIn: Connect with Dan Cosgrove linkedin.com/in/myhealthandwealth [http://linkedin.com/in/myhealthandwealth] Questions, topic ideas, or guest suggestions?Reach out: hello@alignco.life [hello@alignco.life]

Healthy Business Podcast: Movement Capacity Is the Missing Variable in Your Metabolic Strategy

Most employers treat metabolic risk as a chemistry problem. They track A1C. They monitor triglycerides. They debate GLP-1 coverage. They review pharmacy trend lines. And many of those interventions “work.” Weight drops. Labs improve. Claims stabilize. But almost no one asks the harder question: What happens when the intervention stops? In this episode of Healthy Business Matters, Dr. Andrew White argues that metabolic dysfunction doesn’t begin with A1C — it begins when movement becomes expensive. When bending hurts. When knees swell. When sleep is disrupted by pain. When daily activity quietly declines. Because insulin sensitivity isn’t primarily a lab issue. It’s a muscle issue. Muscle is the largest site of glucose disposal in the body. When movement capacity erodes, metabolic stability follows. Here’s the problem: movement capacity doesn’t show up on your dashboard. It doesn’t trigger a large claim. It doesn’t sit neatly inside a CPT code. It doesn’t get flagged in stop-loss reporting. It generates a pathway, not an event. And employers manage events — not pathways. In This Episode, You’ll Learn: Why weight loss without movement capacity is fragile How appetite suppression differs from metabolic strengthening Why muscle mass is metabolic infrastructure How mechanical inflammation drives biochemical instability Why most wellness programs measure activity instead of tolerance The difference between risk management and risk stabilization Why short-term optics often undermine long-term durability The Core Shift Most metabolic strategies reduce load. Very few build structure. Reducing load — through appetite suppression, medication, or calorie restriction — can improve numbers. Building structure — through movement tolerance, muscle preservation, and mechanical stability — improves durability. Those are not the same outcome. If muscle declines while weight declines, you may be improving biomarkers while weakening infrastructure. If pain persists while labs improve, fragility remains. If risk rebounds when the intervention stops, it was never a strategy — it was a subsidy. The 4-Question Durability Framework Before approving or expanding any metabolic or MSK initiative, run it through four filters: Does this increase daily movement tolerance? Not participation. Not logins. Not steps. Does the employee become more capable of bending, lifting, rotating, training, and recovering without friction? Does this preserve or build muscle? Muscle is metabolic infrastructure. Are you strengthening the engine — or simply suppressing the load? Does this reduce mechanical inflammatory input? Inflammation is not only dietary; it’s mechanical. Are joint instability and movement dysfunction being addressed? When the intervention stops, what remains? Is the employee stronger and more stable — or back at baseline? If risk rebounds when the intervention ends, you didn’t fix it. You financed it. Who This Episode Is For Progressive brokers tired of buying short-term optics CFOs who care about durability, not dashboards HR leaders balancing empathy and budget Employers navigating GLP-1 expansion decisions Anyone designing a metabolic strategy that must last beyond a single plan year Healthy Business Matters is built for operators who make real decisions. If this episode sharpened your thinking, share it with a broker, CFO, or HR leader who needs a clearer framework. Follow and subscribe so you don’t miss future episodes. If you’re wrestling with a question inside your own health plan, reach out directly at hello@alignco.life [hello@alignco.life] Clear thinking. Better decisions. Healthier businesses.

Healthy Business Matters: GLP-1's Alone Are Not a Metabolic Strategy

GLP-1s are powerful. They reduce appetite. They lower A1C. They drive meaningful weight loss. For many patients, they are clinically appropriate and life-changing. What’s controversial isn’t the drug. It’s how employers are deploying it. In too many health plans, GLP-1s are being used as the metabolic strategy instead of as a tool inside one. And those are not the same thing. In this episode, Dr. Andrew White breaks down why weight loss alone does not equal metabolic durability and why employers who ignore sequencing, movement capacity, and off-ramps may be increasing long-term pharmacy exposure instead of reducing risk. If you’re a CFO, broker, HR leader, or operator evaluating GLP-1 coverage, this episode gives you a practical framework you can use in your next renewal meeting. What You’ll Learn * Why GLP-1s reduce calories but don’t automatically restore movement capacity * The difference between weight loss and metabolic resilience * Why skeletal muscle is the real metabolic insurance policy * The five-step sequence required for a true employer metabolic strategy * Why most GLP-1 vendors avoid discussing discontinuation * The blind spot almost no GLP-1 programs track: strength and muscle preservation * Five hard questions every CFO should ask before approving coverage The 5-Step Metabolic Strategy Framework 1. Remove inhibitors of movement 2. Restore movement capacity 3. Improve insulin sensitivity intentionally 4. Define the pharmacology off-ramp before starting 5. Reduce long-term pharmacy dependency Because if the drug stops and the risk returns, you didn’t change the pathway you suppressed a symptom Who This Episode Is For * Self-funded employers * CFOs evaluating pharmacy exposure * Brokers navigating competitive GLP-1 pressure * HR leaders caught between recruitment demands and long-term cost control If you care about reducing risk instead of managing optics, this episode is for you. About the Host Dr. Andrew White is the Founder and CEO of AlignWell, a national MSK and metabolic risk management company working with self-funded employers to reduce long-term claims exposure by changing where care starts and how risk is sequenced. If this episode sharpened your thinking: Share it with a broker or CFO who needs a clearer framework Follow/subscribe on Apple or Spotify so you don’t miss future episodes Send topic ideas or renewal questions to hello@alignco.life [hello@alignco.life] Healthy Business Matters is built for people who make real decisions. Clear thinking. Better incentives. Healthier businesses.

Healthy Business Matters: MSK Is The Trojan Horse For Metabolic Risk

Most employers believe they have separate healthcare problems: * An MSK problem * An obesity problem * A GLP-1 problem * A pharmacy trend problem They don’t. They have a pathway problem. In this episode, we connect the dots most benefit strategies keep siloed and make the case that musculoskeletal pain is often the front door to long-term metabolic dysfunction. When something hurts, people move less. When movement drops, insulin sensitivity declines. When metabolism shifts, risk compounds. Months or years later, that shows up in a completely different budget category. By the time you’re debating GLP-1 spend, the pathway was already set. GLP-1 didn’t create your metabolic risk. It revealed it. In This Episode: * Why MSK is often the earliest visible signal of metabolic drift * The physiological cascade from chronic pain → reduced movement → insulin resistance * How untreated MSK quietly compounds pharmacy and catastrophic exposure * Why most employers miss the connection (and why it’s structural, not careless) * Where GLP-1 actually fits inside a coordinated risk strategy * A 3-question framework to evaluate any MSK or metabolic initiative Key Insight Healthcare reporting tells you where you spent money. It rarely tells you where risk began. If you treat MSK as an isolated injury category, you’ll always be managing metabolic risk later. The Framework Before approving any MSK or GLP-1 strategy, ask: 1. Does this change daily movement capacity? 2. Does it improve metabolic stability? 3. Does it alter long-term catastrophic risk — not just this year’s spend? If the answer is no to any one of those, you’re managing a category not engineering trajectory. If you treat the Trojan horse as a back problem, you’ll miss the army inside it. Healthy Business Matters is a thinking platform for progressive brokers, CFOs, and operators who want to move beyond managing healthcare spend; and start engineering risk. Questions, topic ideas, or guest suggestions? Reach out: hello@alignco.life [hello@alignco.life]

Healthy Business Matters: Where Care Starts is Where Costs Are Decided

Where Care Starts Is Where Costs Are Decided Most healthcare costs are locked in long before a diagnosis code ever hits a claim. By the time something shows up in reporting, the damage is already done; not because of fraud, bad doctors, or the wrong vendor, but because of where care started. In this episode of Healthy Business Matters, Dr. Andrew White breaks down a simple but uncomfortable truth: Healthcare costs are driven by pathways, not prices. And if you do not intentionally design the front door to care, the system will design it for you. What This Episode Covers * Why outcomes are decided at the first decision moment, not the back end of claims * A real-world MSK example showing how the same injury produces radically different cost trajectories * How ER, urgent care, and specialist-first pathways quietly create predictable, compounding spend * Why most “proactive” health initiatives stay reactive despite high engagement * The difference between managing spend and actually managing risk The Three MSK Pathways Explained 1. Default System Path * Pain → ER or urgent care * Imaging → referrals → injections → surgery discussions * $8K–$15K episodes that routinely balloon into $30K–$100K+ claims 2. Early Conservative Triage * Pain → MSK-literate first contact * Conservative care first, escalation when appropriate * Imaging used intentionally, not reflexively * Same injury, radically lower cost trajectory 3. Pre-Claim Interception * Onsite screening identifies issues before employees seek care * Movement patterns corrected, loads managed early * No ER visit, no claim, no cascade * Demand never forms in the wrong system The Front Door Test Before buying any health initiative or vendor, ask: 1. Does this change where first contact happens? If it does not influence the first decision moment, it does not change the pathway. 2. Does it reduce friction at the moment of need? Is it easier than the ER? Faster than urgent care? Clearer than Google? 3. Does it redirect demand before claims crystallize? If it only manages claims after imaging and referrals begin, risk control is already gone. If a program cannot answer all three clearly, it is a support program, not a cost-control strategy. Key Takeaway Employers are not overspending because care is expensive. They are overspending because demand is being formed too late and in the wrong place. You cannot manage that downstream. You have to redesign where care begins. Challenge for Employers and Brokers Audit your health strategy by entry point, not by category: * Where does MSK care start? * Where does metabolic care start? * Where does mental health care start? * Where does primary care start? Wherever care starts is where your cost curve is being set. If this episode sharpened your thinking, follow the show and share it with someone responsible for managing risk, not decorating dashboards. New episodes drop every Tuesday.